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ABSTRACT
In the previous chapter, we showed that new and old classes of antihypertensive
drugs have similar long-term efficacy and safety. Furthermore, our meta-analysis
published in June 2003 showed that in clinical trials in hypertensive or high-risk
patients gradients in systolic pressure accounted for most differences in outcome.
To test whether this conclusion would hold, we considered five new outcome tri-
als published before 2005. For these trials, we predicted outcome from achieved
systolic blood pressure using our previously published meta-regression models.
We then contrasted observed odds ratios with those predicted from gradients in
systolic pressure. The main finding of our overview was that reduction in systolic
blood pressure largely explained cardiovascular outcomes in the recently pub-
lished actively controlled trials in hypertensive patients and in placebo-controlled
secondary prevention trials. In conclusion, the hypothesis that new antihyperten-
sive drugs might influence cardiovascular prognosis over and beyond their anti-
hypertensive effect remains unproven. Our overview emphasizes the need of tight
blood pressure control, but does not allow determining to what extent blood pres-
sure must be lowered for optimal cardiovascular prevention.
INTRODUCTION
Until the turn of the millennium, the consensus interpretation of the evidence
produced by the outcome trials in hypertensive patients [1–37] was that blood
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pressure is a risk factor amenable to intervention, lower levels entailing fewer
complications. However, the HOPE trial [38,39] gave rise to the hypothesis that
ACE inhibitors might reduce cardiovascular complications beyond blood pres-
sure control. Subsequently, trials of AR1 blockers in hypertensive patients with
renal failure [40–42] or left-ventricular hypertrophy [43,44] as well as several sec-
ondary prevention trials of ACE inhibitors [45–48] or AR1 blockers [49] sought to
reinforce this hypothesis. However, the results of these trials cannot be inter-
preted without taking into account differences in achieved blood pressure
between randomized groups. The aim of the present review was therefore to
investigate to what extent blood pressure lowering rather than specific ancillary
properties might have contributed to the observed outcome results.
META-REGRESSION ANALYSIS
In 2001 [50,51], we computed the relationship between the odds ratios of experi-
mental vs. reference treatment and the corresponding baseline-corrected differ-
ences in systolic blood pressure between randomized groups. Our
meta-regression analysis [51] involved 30 trials, including 149 407 randomized
patients: nine actively controlled trials (MIDAS [14], CAPPP [25,52], NICS [26],
STOP2 [27], INSIGHT [29,53], NORDIL [30], ALLHAT/Dox [31], VHAS [54] and
UKPDS [24,35]); the HOT trial [20], which investigated three levels of diastolic
blood pressure control; three placebo-controlled trials in isolated systolic hyper-
tension (SHEP [6,8], Syst-China [18,23] and Syst-Eur [9,19,22]); six placebo-con-
trolled trials in normotensive or hypertensive patients at high-cardiovascular
risk (HOPE [38,39], PART2 [33], PATS [12], PROGRESS [28,37,55], SCAT [34] and
RENAAL [41]) and 11 older trials testing the efficacy of antihypertensive drugs
against no treatment (HEP [2] and OSLO [13]) or placebo (ATMH [11], EWPHE
[1,56], HSCS [15], MRC1 [5], MRC2 [4], STOP1 [3], STONE [7], USPHS [16], and
VACS [17]). We did not include seven studies, because fewer than 100 patients
had been randomized [57–59], follow-up had been less than 2 years [60,61],
insufficient information had been published on achieved systolic blood pressure
(HDFP [62,63]) or nonfatal outcomes (CASTEL [64]) and/or because randomiza-
tion was between usual and referred care (CASTEL [64] and HDFP [62,63]).
As previously reported [50,51,65], the meta-regression line relating the odds
ratios for cardiovascular mortality (Fig. 30.1, left panel) to the corresponding
within-trial differences in systolic pressure, was linear. For all cardiovascular
events (Fig. 30.1, right panel), stroke (Fig. 30.2, left panel) and myocardial infarc-
tion (Fig. 30.2, right panel), these relations were curvilinear. For these combined
fatal and nonfatal outcomes, there was no further benefit if the within-trial dif-
ferences in systolic blood pressure exceeded ~15 mmHg. Because in our meta-
regression analysis [50,51,65], the odds ratios respected the randomization and
because within each trial, patients had similar characteristics at entry, adjust-
ment for the baseline systolic pressure did not materially alter the position of the
regression lines.
In our first reviews [50,51,65], we compared observed odds ratios and those
that could be predicted by meta-regression from the baseline-adjusted differences
in achieved systolic blood pressure between randomized groups. Among six tri-
als of new vs. old drugs (ALLHAT/Dox [31], CAPPP [25,52], MIDAS [14], NICS
[26], NORDIL [30] and VHAS [54]) and four placebo-controlled trials (HOPE
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[38,39], PART2 [33], PROGRESS [28,37,55] and SCAT [34]), the gradients in
achieved systolic blood pressure ranged from 1.8 mmHg [14] to 12.0 mmHg [37].
Differences between observed and predicted odds ratios were not significant
apart from those for stroke in NORDIL [30] and PROGRESS/Per [28,37,55]. In the
former study [30], the risk was lower in patients on diltiazem than on old drugs
despite systolic blood pressure that was 3.1 mmHg higher on the calcium-chan-
nel blocker (Table 30.1). In PROGRESS/Per [37], monotherapy with perindopril
compared to placebo-reduced systolic blood pressure by 5.0 mmHg, but had no
influence on stroke recurrence or the incidence of all cardiovascular events.
In our 2003 update [66], we considered seven additional studies allowing
comparison of outcomes on new vs. old drugs (ALLHAT [67], ANBP2 [68],
CONVINCE [69], ELSA [70,71], HYVET/AD [72], LIFE [10,43,44,73] and SCOPE
[74–76]). The characteristics of these trials were described in the previous chap-
ter. Taking conventional therapy with diuretics and β-blockers as the reference,
the achieved systolic pressure was higher on amlodipine in ALLHAT/Aml (1.1
mmHg), on lisinopril in ALLHAT/Lis (2.3 mmHg), and on ACE inhibitors in
ANBP2 (2.0 mmHg). In contrast, in LIFE/All (1.1 mmHg) and LIFE/DM (3.0
mmHg) as well as in SCOPE (3.2 mmHg), systolic blood pressure was signifi-
cantly higher in the reference group on conventional therapy than in the patients
30
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Fig. 30.1 Odds ratios for cardiovascular mortality (left panel) and all cardiovascular events (right
panel) in relation to corresponding differences in systolic blood pressure. Odds ratios were calcu-
lated for experimental vs. reference treatment. Blood pressure differences were obtained by sub-
tracting achieved levels in experimental groups from those in reference groups. Negative values
indicate tighter blood pressure on control than on reference treatment. The regression lines were
plotted with 95% confidence interval and were weighted for the inverse of the variance of the indi-
vidual odds ratios. Open symbols denote placebo-controlled studies or trials with an untreated
control group. Closed symbols indicate actively controlled trials. Acronyms of trials are explained in
a separate section of the article. Reproduced with permission from Ref. [50].
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allocated losartan or candesartan, respectively. In general, for none of the
reviewed outcomes in any of these trials, we detected significant differences
between the observed and predicted odds ratios [66]. Myocardial infarction and
consequently all cardiovascular events in the ANBP2 trial [68] constituted the
only significant exception (P = 0.02, Table 30.1). In the ANBP2 patients random-
ized to ACE inhibition, systolic blood pressure was on average 2.0 mmHg higher
than in those allocated diuretic treatment [68]. The predicted odds ratios there-
fore tended to be higher than unity, whereas for all cardiovascular events (1.15
vs. 0.90) and myocardial infarction (1.08 vs. 0.70), the opposite was observed. For
myocardial infarction (Table 30.1), borderline differences between predicted vs.
observed odds ratios in favor of ACE inhibition were also observed in ALL-
HAT/Lis, both in all patients (1.14 vs. 0.98; P = 0.08) and in those aged 65 years
or more (1.20 vs. 1.01; P = 0.08).
In our 2003 update [66], we also reviewed two trials of tight vs. usual blood
pressure control (AASK [77–79] and ABCD/NT [80]) and five placebo-
controlled designs (DIABHYCAR [47,81,82], HYVET/BP [7, the achieved sys-
tolic pressure was higher on amlodipine in ALLHAT/Aml (1.1 mmHg), on
lisinopril in ALLHAT/Lis (2.3 mmHg), and on ACE inhibitors in ANBP2 (2.0
mmHg). In contrast, in LIFE/All (1.1 mmHg) and LIFE/DM (3.0 mmHg) as well
as in SCOPE (3.2 mmHg), systolic blood pressure was significantly higher in the
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Fig. 30.2 Odds ratios for fatal and nonfatal stroke (left panel) and fatal and nonfatal myocardial
infarction (right panel) in relation to corresponding differences in systolic blood pressure. Odds
ratios were calculated for experimental vs. reference treatment. Blood pressure differences were
obtained by subtracting achieved levels in experimental groups from those in reference groups.
Negative values indicate tighter blood pressure on control than on reference treatment. The regres-
sion lines were plotted with 95% confidence interval and were weighted for the inverse of the vari-
ance of the individual odds ratios. Open symbols denote placebo-controlled studies or trials with
an untreated control group. Closed symbols indicate actively controlled trials. Acronyms of trials
are explained in a separate section of the article. Reproduced with permission from Ref. [50].
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reference group on conventional therapy than in the patients allocated losartan
or candesartan, respectively. In general, for none of the reviewed outcomes in
any of these trials, we detected significant differences between the observed and
predicted odds ratios [66]. Myocardial infarction and consequently all cardio-
vascular events in the ANBP2 trial [68] constituted the only significant exception
(P = 0.02, Table 30.1). In the ANBP2 patients randomized to ACE inhibition, sys-
tolic blood pressure was on average 2.0 mmHg higher than in those allocated
diuretic treatment [68]. The predicted odds ratios therefore tended to be higher
than unity, whereas for all cardiovascular events (1.15 2], IDNT2 [40,45,83],
NICOLE [84,85] and PREVENT [86,87]) (see previous chapter for a description
of these trials). For these seven trials [45,47,72,79,80,85,87], observed and pre-
dicted odds ratios were similar with the exception of cardiovascular mortality in
HYVET/BP (Table 30.1). In spite of a 22.5 mmHg lower systolic blood pressure
in the patients randomized to active treatment than in those left untreated, car-
diovascular mortality did not decrease (observed vs. predicted odds ratios, 1.19
vs. 0.55; P = 0.02). For all cardiovascular events in AASK [79], the observed odds
ratios tended to be higher than predicted (0.88 vs. 0.60; P = 0.07 [79]).
Among the most recently published trials, including ACTION [88,89], INVEST
[90], SHELL [91], VALUE [49,92] (for a description of these trials, see previous
chapter), ACTION [88,89] (Table 30.1) revealed discordance between observed
and predicted odds ratios for cardiovascular mortality (1.01 vs. 0.81; P = 0.06),
cardiovascular events (0.94 vs. 0.73; P = 0.0001) and myocardial infarction (1.04
vs. 0.76; P = 0.002), but not stroke (0.78 vs. 0.78; P = 0.39). In VALUE [49,92], with
regard to myocardial infarction, the observed outcome on valsartan was worse
than predicted (1.19 vs. 0.98; P = 0.03) or conversely that of amlodipine-based
treatment was better than predicted from the gradient in the achieved systolic
blood pressure (0.84 vs. 1.02; P = 0.03; Table 30.1). Fig. 30.3 provides detailed
information on observed and predicted odds ratios for stroke (left panel) and
myocardial infarction (right panel) in five placebo-controlled secondary preven-
tion studies of dihydropyridine calcium-channel blockers [45,85,87,88,93].
Fig. 30.4 gives similar results for eight placebo-controlled secondary intervention
trials of ACE inhibitors [33,34,37,38,46–48,93].
INTERPRETATION OF THE EVIDENCE
The main finding of our meta-regression analysis was that large reduction in
systolic blood pressure explained the cardiovascular outcomes in the recently
published actively controlled trials in hypertensive patients and in the placebo-
controlled secondary prevention trials.
Our previous meta-regression analyses [50,51,66] along with the present
overview considered 45 trials in total {15, 17, 60, 65, 192, 193, 247, 488, 528, 750,
786, 863, 922, 923, 927, 934, 960, 961, 974, 1196, 1328, 1329, 1351,1514, 1580, 1702,
1760, 1761, 1778, 1779, 1802, 1803, 1805. 1806, 1814, 2007, 2015, 2016, 2506, 2507,
2637, 2704, 2736, 2798, 2814, 2821, 2830, 2838, 2858, 2920, 2998, 3057, 3073, 3089,
3124, 3125, 3135, 3165, 3177, 3237, 3261}. Several of these trials involved multiple
comparisons of various active drugs with placebo or with each other. From each
trial and for each comparison, we tried to extract information on cardiovascular
mortality, cardiovascular morbidity, stroke and myocardial infarction. A substan-
tial number of the reviewed trials [37,44–49,67–70,72,75,79,80,85,87,88,90,91,93]
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announced their results after 2001, when we had first published our meta-regres-
sion models [50]. To standardize our analysis, we did not use adjusted relative
risks as published in many articles. Instead, we recalculated the observed odds
ratios from the number of events and the number of patients per group random-
ized in each trial by use of 2 × 2 contingency tables [50]. Across all reviewed trials
and endpoints, only in 14 instances we found a significant or borderline signifi-
cant difference between observed and predicted odds ratios. These findings
underscore that the outcome results of most trials in patients with hypertension
or high-cardiovascular risk should be attributed to the within-trial differences in
systolic blood pressure. This point of view is also in line with the observational
prospective evidence. Indeed, in middle-aged and older patients, systolic pres-
sure is the prevailing blood pressure component with regard to cardiovascular
prognosis [94,95]. In a quantitative overview involving 1 million subjects, the
Prospective Studies Collaboration demonstrated that small gradients in blood
pressure similar to those observed in recent trials might account for substantial
differences in cardiovascular outcomes [96].
For myocardial infarction (0.70 vs. 1.08) in the ANBP2 trial [68], and hence for
all cardiovascular events (0.90 vs. 1.15), the odds ratios for therapy with
ACE inhibitors vs. conventional therapy were significantly lower than those
30
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Fig. 30.3 Observed vs. predicted odds ratios for stroke in five placebo-controlled secondary pre-
vention trials of dihydropyridine calcium-channel blockers (DHP, top) and eight placebo-controlled
secondary prevention trials of ACE inhibitors (ACEI, bottom). Predicted odds ratios were derived by
meta-regression (Fig. 5). For each trial, the total number of patients analyzed and the percent of
patients who experienced an event are given. P-values are for the comparison between observed
and predicted odds ratios. Acronyms of trials are explained in a separate section of the article.
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predicted by the achieved systolic blood pressure, which was 2.0 mmHg higher
in the patients on ACE inhibitors. Similar trends were also observed for myocar-
dial infarction in the lisinopril arm of the ALLHAT trial [67], both in all patients
(0.98 vs. 1.14) and in those aged 65 years or more (1.01 vs. 1.20), whose systolic
blood pressure was 2.3 and 3.0 mmHg higher, respectively, than in the corre-
sponding controls randomized to chlorthalidone. Thus, if one accounts for
achieved systolic pressure, ACE inhibitors in Caucasian hypertensive patients
seem to offer a slightly greater protection against coronary complications than
conventional therapy. These findings are in-line with the secondary prevention
trials in patients with acute myocardial infarction [97,98]. CAMELOT [93] and
PEACE [48] only reported the incidence of nonfatal myocardial infarction, which
in the context of the endpoint definitions used in the present overview does not
facilitate the interpretation in relation to blood pressure.
The achieved systolic blood pressure levels and associated stroke rates in the
lisinopril arm of the ALLHAT trial [67] corroborated the concept that older and
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Fig. 30.4 Observed vs. predicted odds ratios for myocardial infarction in five placebo-controlled
secondary prevention trials of dihydropyridine calcium-channel blockers (DHP, top) and eight
placebo-controlled secondary prevention trials of ACE inhibitors (ACEI, bottom). Predicted odds
ratios were derived by meta-regression (Fig. 5). For each trial, the total number of patients analyzed
and the percent of patients who experienced an event are given. P-values are for the comparison
between observed and predicted odds ratios. Acronyms of trials are explained in a separate sec-
tion of the article.
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black patients usually have a low-renin volume-expanded type of hypertension,
which responds better to initial treatment with diuretics or calcium-channel
blockers [99–102]. In two trials comparing AR1 blockers [44,75] with conven-
tional therapy, lower achieved systolic blood pressure explained the better out-
comes on losartan [43,44] or candesartan [103]. Both trials had a double-blind
design, but they were also characterized by the more frequent discontinuation of
the double-blind study medication in the control group [44,103] and the more
frequent use of open-label drugs either in the experimental [44] or in the control
[103] group. The systolic gradient was larger in SCOPE [103] than in LIFE
[43,44], but the P-value for heterogeneity in the stroke outcomes between these
two trials was nonsignificant. Thus, as discussed elsewhere [104], our present
findings are at variance with the LIFE investigators’ interpretation that claimed
benefit beyond blood pressure control for losartan vs. atenolol [43,44]. To what
extent unopposed stimulation of the type 2 angiotensin II receptor in the brain
contributes to the divergent stroke outcomes on ACE inhibitors and AR1-recep-
tor blockers relative to conventional therapy remains to be elucidated [105].
Two instances in which there was a significant deviation between observed
and predicted odds ratios highlight the need for further research. First, in the
pilot run of the HYVET trial [72], active treatment compared to no intervention
lowered systolic blood pressure by 22.5 mmHg, but did not reduce cardiovascu-
lar mortality. The observed and predicted odds ratios were 1.19 vs. 0.55, respec-
tively. Second, in the AASK trial [78,79], intensive blood pressure lowering
compared to usual care led to a 16.0 mmHg difference in systolic blood pressure
with less reduction in the cardiovascular event rate than expected (odds ratios
0.88 vs. 0.60).
We did not compute a meta-regression line for heart failure, because among
the 30 trials in our 2001 overview [50], only 13 reported on this endpoint and
because the criteria for its diagnosis were not standardized across trials. In their
2003 report [106], the Blood Pressure Lowering Treatment Trialists’ Collaboration
observed that for every outcome other than heart failure, the differences between
randomized groups in cardiovascular outcomes were directly related to the
achieved systolic blood pressure. However, the lack of association for heart fail-
ure was mainly due to four trials, which compared calcium-channel blockers to
placebo and which included IDNT2 [40,45,83], NICOLE [84,85], PREVENT
[86,87] and Syst-Eur [9,19,22]. The question remains whether from a clinical point
of view combination of one primary prevention trial in older patients with iso-
lated systolic hypertension [9] and three secondary prevention studies in diabetic
patients with renal dysfunction [45] or in high-risk patients with coronary heart
disease [85,87] is useful, because of the substantial differences in the pathophysio-
logic mechanisms causing left-ventricular failure in such heterogeneous patient
groups [107,108].
CONCLUSIONS
The hypothesis that new antihypertensive drugs, such as calcium-channel block-
ers, β-blockers, ACE inhibitors or AR1 blockers might influence cardiovascular
prognosis over and beyond their antihypertensive effect remains unproven. In the
primary and secondary prevention trials of blood pressure lowering drugs, the
achieved systolic blood pressure was the major determinant of cardiovascular
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outcome. This observation is in keeping with recent findings in Syst-Eur [109] and
VALUE [49,92], which highlighted that immediate blood pressure lowering and
early blood pressure control are key determinants of cardiovascular prognosis.
Although a number of secondary prevention trials included normotensive
patients, the level to which blood pressure must be lowered to achieve maximal
benefit remains to be clarified.
The relevance of achieved blood pressure for cardiovascular prognosis must
be gauged in terms of the poor control rates of systolic blood pressure in the pop-
ulation at large [110] as well as in primary care [111]. If blood pressure is the
major determinant of prognosis, the inescapable inference is that antihyperten-
sive therapy should be individualized and initiated with the drug class that is
most likely to be active in each individual patient, taking into account his overall
risk profile and comorbid conditions [112]. In over 60% of patients, optimization
of treatment at acceptable levels of tolerance requires rotation through and com-
bination of several drug classes. The blood pressure lowering activities of ACE
inhibitors and β-blockers are additive to those of thiazides and calcium-channel
blockers and vice versa [101,102]. Patients younger than 50 years may be started
on ACE inhibitors or β-blockers and switched to combination therapy with
either thiazides or calcium-channel blockers if blood pressure remains uncon-
trolled, whereas older patients may proceed in the reverse order [101,102]. In this
context, the debate over which drug class is best suited to start antihypertensive
therapy is largely elusive.
Several studies have indicated that overall blood pressure control is particu-
larly poor in patients with isolated systolic hypertension [113]. This could partly
be due to the fact that treatment decisions are often based on diastolic blood pres-
sure rather than on systolic blood pressure. In addition, antihypertensive drugs
are usually more effective in reducing diastolic blood pressure. New drugs that
are specifically adapted to the pathophysiology of systolic hypertension through
an effect on arterial stiffness and wave reflections should be developed.
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ACRONYMS OF TRIALS
AASK, the African American Study of Kidney disease and hypertension
[77–79,114]; ABCD, Appropriate Blood Pressure Control in Diabetes trial
[80,115–118]; ABCD/HT, Appropriate Blood Pressure Control in Diabetes trial –
nisoldipine vs. enalapril in hypertensive patients [115,117,118]; ABCD/NT,
Appropriate Blood Pressure Control in Diabetes trial – tight vs. usual blood pres-
sure control in normotensive hypertensive patients [80]; ACTION, A Coronary
disease Trial Investigating Outcome with Nifedipine GITS [88,89]; ALLHAT,
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
[67]; ALLHAT/Aml, Antihypertensive and Lipid-Lowering Treatment to Prevent
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Heart Attack Trial – amlodipine vs. chlorthalidone [67]; ALLHAT/Dox,
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial –
doxazosin vs. chlorthalidone [31,119]; ALLHAT/Lis, Antihypertensive and
Lipid-Lowering Treatment to Prevent Heart Attack Trial – lisinopril vs. chlorthali-
done [67]; ANBP2, Australian comparative outcome trial of angiotensin-convert-
ing enzyme inhibitor- and diuretic-based treatment of hypertension in the elderly
[68]; ASCOT, the Anglo-Scandinavian Cardiac Outcomes Trial [120,121]; ATMH,
Australian Trial in Mild Hypertension [11]; BENEDICT, BErgamo NEphrologic
DIabetes Complications Trial [122,123]; CAMELOT, Comparison of AMlodipine
vs. Enalapril to Limit Occurrences of Thrombosis [93]; CAMELOT/Aml,
Comparison of AMlodipine vs. Enalapril to Limit Occurrences of Thrombosis –
amlodipine vs. placebo [93]; CAMELOT/En, Comparison of AMlodipine vs.
Enalapril to Limit Occurrences of Thrombosis – enalapril vs. placebo [93]; CAS-
TEL, CArdiovascular STudy in the ELderly [64]; CALM, CAndesartan and
Lisinopril Microalbuminuria study [124]; CAPPP, Captopril Prevention
Project [25,52]; CONVINCE, Controlled Onset Verapamil Investigation of
Cardiovascular Endpoints trial [69]; DIABHYCAR, the noninsulin-dependent
DIAbetes, HYpertension, microalbuminuria or proteinuria, CArdiovascular
events, and Ramipril study [47,81,82]; ELSA, European Lacidipine Study on
Atherosclerosis [70,71]; EUROPA, EURopean trial On reduction of cardiac events
with Perindopril in stable coronary Artery disease [46]; EWPHE, trial conducted
by the European Working Party on High Blood Pressure in the Elderly [1,56];
HEP, trial of Hypertension in Elderly Patients in primary care [2]; HDFP,
Hypertension Detection and Follow-Up Program [62,63]; HOPE, Heart
Outcomes Prevention Evaluation Study [38,39]; HOT, Hypertension Optimal
Treatment trial [20]; HOT/LH, Hypertension Optimal Treatment trial [20] – 80 vs.
90 mmHg as target diastolic pressure; HOT/MH, Hypertension Optimal
Treatment trial [20] – 85 vs. 90 mmHg as target diastolic pressure; HYVET,
HYpertension in the Very Elderly Trial pilot trial [72]; HYVET/AD, HYpertension
in the Very Elderly Trial pilot trial – ACE inhibition vs. diuretic treatment [72];
HYVET/BP, HYpertension in the Very Elderly Trial pilot trial – blood pressure
lowering drugs vs. no treatment [72]; IDNT2, Irbesartan Diabetic Nephropathy
Trial in patients with type 2 diabetes mellitus [40,45,83]; INSIGHT, International
Nifedipine GITS Study-Intervention as a Goal for Hypertension Therapy [29,53];
IRMA2, Irbesartan in patients with type 2 diabetes and MicroAlbuminuria
study[42]; INVEST, INternational VErapamil SR/trandolapril STudy [90]; JMIC-
B, the Japan Multicenter Investigation for Cardiovascular diseases-B [125]; LIFE,
Losartan Intervention For Endpoint Reduction in hypertension study
[10,43,44,73]; LIFE/All, Losartan Intervention For Endpoint Reduction in hyper-
tension study – all patients [44]; LIFE/DM, Losartan Intervention For Endpoint
Reduction in hypertension study – diabetic subgroup [43]; HSCS,
Hypertension–Stroke Cooperative Study [15]; MIDAS, Multicenter Isradipine
Diuretic Atherosclerosis Study [14]; MIDAS/NICS/VHAS, combined results of
MIDAS, [14] NICS [26] and VHAS [32]; MRC1, Medical Research Council trial of
treatment of mild hypertension [5]; MRC2, Medical Research Council trial of
treatment of hypertension in older adults [4]; NICOLE, NIsoldipine in COronary
artery disease in LEuven [84,85]; NICS, National Intervention Cooperative Study
in Elderly Hypertensives [26]; NORDIL, Nordic Diltiazem Study [30]; OSLO,
Oslo Study on the Treatment of Mild Hypertension [13]; PART2, Prevention of
Atherosclerosis with Ramipril Trial [33]; PART2/SCAT, combined results of
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PART2 [33] and SCAT [34]; PATS, Post-stroke Antihypertensive Treatment Study
[12]; PEACE, Prevention of Events with Angiotensin-Converting Enzyme inhibi-
tion [48]; PREVENT, Prospective Randomized Evaluation of the Vascular Effects
Norvasc Trial [86,87]; PROGRESS, Perindopril PrOtection Against Recurrent
Stroke Study [28,37,55]; PROGRESS/Com, Perindopril PrOtection Against
Recurrent Stroke Study [28,37,55] – group on combined therapy;
PROGRESS/Per, Perindopril PrOtection Against Recurrent Stroke Study
[28,37,55] – group on single-drug treatment; REIN, Ramipril Efficacy In
Nephropathy trial [126]; RENAAL, Reduction of Endpoints in NIDDM with the
Angiotensin II Antagonist Losartan [41]; RCT70-80, combined results of four
smaller trials published from 1970 through 1980, including HSCS, [15] OSLO, [13]
USPHS, [16] and VACS [17]; SCAT, Simvastatin/Enalapril Coronary
Atherosclerosis Trial [34]; SCOPE, Study on COgnition and Prognosis in the
Elderly [74–76]; SHELL, Systolic Hypertension in the Elderly Long-term
Lacidipine trial [91]; SHEP, Systolic Hypertension in the Elderly Program [6,8];
STONE, Shanghai Trial of Nifedipine in the Elderly [7]; STOP1, Swedish Trial in
Old Patients with hypertension [3]; STOP2, Swedish Trial in Old Patients with
hypertension-2 [27]; STOP2/ACEIs, angiotensin-converting enzyme inhibitor
arm of STOP2 [27]; STOP2/CCBs, calcium-channel blocker arm of STOP2 [27];
Syst-China, Systolic Hypertension in China trial [18,23]; Syst-Eur, Systolic
Hypertension in Europe trial [9,19,22]; TEST, Tenormin after Stroke and TIA [127];
UKPDS, UKPDS Hypertension in Diabetes Study [24,35]; UKPDS/CA, UKPDS
Hypertension in Diabetes Study – captopril vs. atenolol [35]; UKPDS/LH,
UKPDS Hypertension in Diabetes Study – low vs. high on-treatment blood pres-
sure [24]; USPHS, United States Public Health Service Hospitals Cooperative
Study [16]; VACS, Veterans Administration Cooperative Study in patients with
diastolic blood pressure averaging 90–114 mmHg [17]; VALUE, Valsartan
Antihypertensive Long-term Use Evaluation [49,92,128–130]; VHAS, Verapamil
in Hypertension and Atherosclerosis Study [54].
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